randomised trial

Second pass at: Journal club: STEP 4 and what a withdrawal design can prove Writing it up because I had to work it out twice and would rather nobody else did. The question about STEP 4 that I actually want…

Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? A question about dual agonism that I think has a definite answer, unlike most of what I…

Posting this under the heading it deserves: Journal club: indirect comparison between two programmes, defended and attacked — one year on Everything below is what sits behind that. Asking about indirect…

On the subject in the title: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Working notes rather than a conclusion. I would like to disagree carefully with the settled view on…

Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…

Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version A narrow question about GIP…

The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Glucagon receptor…

Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin trial registration down and I want to…

Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Reading back through what has been written here…

Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…

Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…

On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Posting a small dataset on step-hfpef and symptom endpoints. It is mine,…

Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? A methods question rather than a substantive one,…

The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. I would like to know…

Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…

On the subject in the title: Sample size calculations, read backwards from the published number Working notes rather than a conclusion. Sample size calculations — I have the observation and I do not trust my…

What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question…

Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. The question about step-hfpef and symptom endpoints that I actually want answered is the…

Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. Working notes on cagrisema phase 2 paper rather than a…

SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…

On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. A narrow question about Comparing the STEP programme…

Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. Tirzepatide molecular mass keeps being re-asked here…

Journal club: is percentage weight change the right endpoint? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about what the numbers mean rather than what…

On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…

Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. Reading back through what has been written here about Tirzepatide in…

Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…

On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…

Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Comparators chosen for…

Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about cagrilintide…

On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue…